ArticleFrontiers in endocrinology2026
Does ovarian stimulation accelerate the progression of BI-RADS categories? a propensity score matching-based retrospective cohort study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate whether controlled ovarian stimulation (COS), as part of assisted reproductive technology (ART), accelerates the progression of BI-RADS categories. Methods: This was a single-center, retrospective, propensity score matching (PSM) cohort study conducted from January 2020 to January 2025. A total of 9, 632 women were initially enrolled. After 1:1 PSM, the final analyzed cohort comprised 229 pairs of women aged <35 years (younger group) and 154 pairs of women aged ≥35 years (older group). The exposed group comprised women who underwent COS for IVF/ICSI treatment, while the control group consisted of women who underwent routine physical examinations during the same period with no history of ART treatment. The primary outcome was the change (escalation or regression) in BI-RADS category from baseline to follow-up (≥12 months), blindly re-evaluated by two senior sonographers. Propensity score matching was performed to balance baseline characteristics between groups, and subgroup and trend analyses were conducted. Results: After PSM, baseline characteristics were well balanced between the groups. In the <35 years cohort, the exposed group showed significantly higher rates of both BI-RADS category escalation (30.13% vs. 13.54%, P = 0.019) and regression (14.84% vs. 6.98%, P = 0.007) compared with the control group. In the ≥35 years cohort, the escalation rate was significantly higher in the exposed group than in the control group (36.36% vs. 12.33%, P<0.001), whereas no significant difference was observed in regression rates. Trend analysis revealed that among women aged ≥35 years, the risk of BI-RADS category escalation increased significantly with the number of stimulation cycles (trend P = 0.04). All 12 patients who underwent biopsy due to escalation to BI-RADS 4A had benign pathological findings. Regarding pregnancy outcomes, the <35 years group demonstrated significantly higher clinical pregnancy and live birth rates, as well as a lower miscarriage rate, compared with the ≥35 years group. Conclusion: COS is associated with an increased short-term risk of BI-RADS category progression, particularly among women aged ≥35 years. However, it is crucial to note that all 12 patients who underwent biopsy following an upgrade to BI-RADS 4A had benign pathological findings. This suggests that the observed imaging changes may represent a transient, hormone-driven breast tissue response rather than an indicator of malignant transformation. The higher regression rate observed in younger women in the exposed group may be related to subsequent pregnancy and lactation, but this remains speculative. These findings highlight the importance of age-stratified imaging surveillance during ART, rather than implying an elevated risk of breast cancer. Long-term prospective studies are warranted to validate these observations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.